º¬Ð߲ݴ«Ã½

Annual report pursuant to Section 13 and 15(d)

Stock-Based Compensation (Tables)

v3.22.0.1
Stock-Based Compensation (Tables)
12 Months Ended
Dec. 31, 2021
Stock-Based Compensation Ìý
Schedule of number and weighted average GDFV of option granted

​

​

​

​

​

​

​

​

​

​

​

​

​

​

​

​

​

​

​

For the Years ended December 31,

​

​

​

2021

​

2020

​

2019

​

​

​

Options Granted (000's)

​

Weighted Average GDFV

​

Options Granted (000's)

​

Weighted Average GDFV

​

Options Granted (000's)

​

Weighted Average GDFV

​

​

​

​

​

​

​

​

​

​

​

​

​

​

​

​

​

​

Series A º¬Ð߲ݴ«Ã½ common stock, QVC and HSN employees (1)

​

895

​

$

6.75

​

4,200

​

$

1.96

​

2,503

​

$

4.07

​

Series A º¬Ð߲ݴ«Ã½ common stock, Zulily employees (1)

​

79

​

$

6.74

​

618

​

$

1.94

​

328

​

$

4.08

​

Series A º¬Ð߲ݴ«Ã½ common stock, º¬Ð߲ݴ«Ã½ employees and directors (2)

​

63

​

$

6.18

​

747

​

$

4.86

​

639

​

$

3.97

​

Series A º¬Ð߲ݴ«Ã½ common stock, David Rawlinson II (3)

​

1,185

​

$

5.02

​

NA

​

​

NA

​

NA

​

​

NA

​

Series A º¬Ð߲ݴ«Ã½ common stock, º¬Ð߲ݴ«Ã½ Chairman of the Board (4)

​

NA

​

​

NA

​

1,191

​

$

4.88

​

2,134

​

$

3.44

​

Series B º¬Ð߲ݴ«Ã½ common stock, º¬Ð߲ݴ«Ã½ Chairman of the Board (4)

​

NA

​

​

NA

​

NA

​

​

NA

​

26

​

$

5.84

​

(1) Vests semi-annually over four years.
(2) Vests between two and five years for employees and in one year for directors.
(3) Vests in two equal tranches on December 31, 2023 and December 31, 2024. Grant was made in connection with Mr. Rawlinson’s employment agreement (see note 10).
(4) The grants made in December 2020 and December 2019 in connection with the Chairman’s new employment agreement cliff vest in December 2024 and December 2023, respectively. The grant made in March 2019 vested immediatelyand was made in connection with the Chairman’s previous employment agreement (see notes 1 and 10).
Schedule of Share-based Payment Award, Stock Options, Valuation Assumptions

​

​

​

​

​

​

​

​

​

​

Volatility

Ìý

​

ÌýÌýÌýÌý

ÌýÌýÌýÌý

ÌýÌýÌýÌý

ÌýÌýÌýÌý

ÌýÌýÌýÌý

​

2021 grants

Ìý

53.7

%ÌýÌý

-

57.1

%ÌýÌý

2020 grants

Ìý

46.8

%ÌýÌý

-

54.8

%ÌýÌý

2019 grants

Ìý

30.1

%ÌýÌý

-

44.8

%ÌýÌý

Schedule of number, weighted average exercise price ("WAEP"), Weighted average remaining life and aggregate intrinsic value of the awards

​

​

​

​

​

​

​

​

​

​

​

​

​

​

​

​

​

​

​

​

​

​

​

​

​

​

​

º¬Ð߲ݴ«Ã½

Ìý

​

​

SeriesÌýA

​

SeriesÌýB

Ìý

​

​

​

​

​

​

​

Weighted

​

Aggregate

​

​

​

​

​

​

Weighted

​

Aggregate

​

​

​

​

​

​

​

​

average

​

Ìýintrinsic

​

​

​

​

​

​

average

​

Ìýintrinsic

​

​

​

Awards

​

​

​

​

remaining

​

value

​

Awards

​

​

​

​

remaining

​

value

​

​

ÌýÌýÌýÌý

(000's)

ÌýÌýÌýÌý

WAEP

ÌýÌýÌýÌý

life

ÌýÌýÌýÌý

(in millions)

ÌýÌýÌýÌý

(000's)

ÌýÌýÌýÌý

WAEP

ÌýÌýÌýÌý

life

ÌýÌýÌýÌý

(in millions)

Ìý

Outstanding at JanuaryÌý1, 2021

​

40,553

​

$

10.61

​

​

​

​

​

​

​

3,243

​

$

15.39

​

​

​

​

​

​

Ìý

Granted

Ìý

2,222

​

$

11.63

​

​

​

​

​

​

Ìý

—

​

$

—

​

​

​

​

​

​

​

Exercised

Ìý

(2,822)

​

$

5.60

​

​

​

​

​

​

Ìý

—

​

$

—

​

​

​

​

​

​

​

Forfeited/Cancelled

Ìý

(3,899)

​

$

12.76

​

​

​

​

​

​

Ìý

(1,335)

​

$

16.93

​

​

​

​

​

​

​

November Special Dividend adjustment

​

6,056

​

$

9.24

​

​

​

​

​

​

​

313

​

$

12.33

​

​

​

​

​

​

​

Outstanding at December 31, 2021

Ìý

42,110

​

$

9.23

Ìý

3.4

years

​

$

58

Ìý

2,221

​

$

12.25

Ìý

1.8

years

​

$

—

​

Exercisable at December 31, 2021

Ìý

25,249

​

$

11.80

Ìý

2.2

years

​

$

10

Ìý

2,221

​

$

12.25

Ìý

1.8

years

​

$

—

​